Cetuximab biomarker study

Cetuximab biomarker study - C-MAb BM study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002165

Enrollment

Registered

2009-08-10

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent or metastatic colorectal cancer

Interventions

Cetuximab and Irinotecan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.adenocarcinoma histology 2.primary site: colon or rectum 3.metastatic or recurrent disease 4.EGFR(IHC) positive 5.K-RAS Wild type in case of EGFR negative 6.above 20 y.o. 7. PS 0-1 8. prior chemotherapy with fluoropirimidine, L-OHP, irinotecan 9. no prior tretment with EGFR inhibitors 10. at least one measurable lesion 11. written informed consent form

Exclusion criteria

Exclusion criteria: 1.active synchronous malignancy 2.pregnancy 3.severe psychological disease 4.systemic steroid administration 5.HBV carrier 6.uncontrolled diabetes 7.severe fluid collection 8.bowel obstruction 9.cardiovasucular disease within 3months 10.severe comorbidity 11.active infection

Design outcomes

Primary

Measure	Time frame
correlatopn between biomarkers and efficacy and side effects of cetuximab	—

Countries

Japan

Contacts

Public ContactNaomi Kiyota

Kobe University Hospital Medical Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026